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INTRODUCTION
According to the 2008 World Health Organization (WHO) 
report, major depressive disorder (MDD) had overtake acquired 
immune deficiency syndrome (AIDS), cardiovascular disease, and 
cancer and ranked in the top three of high burden and disability dis-
eases in the world, first in middle-and-high-income countries, and 
predicted to be the world’s top first by the year 2030.[1] However, 
this disability brings serious economic loss in the modern society. 
In the United States, MDD caused 77.4 billion USD in 1997 and 
elevated to 97.3 billion USD in 2008.[2,3] Suicidal behaviors are 
the most terrible result of MDD patients. Suicide had been one 
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ABSTRACT
According to the prediction of the 2008 World Health Organization (WHO) report, depression will be the highest burden disease by the 
year 2030. Daylily flower (金針花 Jīn Zhēn Huā ; the flower of Hemerocallis fulva) is traditionally used for soothing in Chinese dietary 
therapy. The major flavonoid of daylily flowers, rutin, is also characterized to be an antidepressant. In this study, we investigated the 
antidepressant effects of ethanol extract of daylily flowers (DFEtoH) and rutin by forced swimming test (FST) and neurotransmitter 
metabolism of brain regions (frontal cortex, hippocampus, striatum, and amygdala). Results show that either short- or long-term tests, 
the extract and rutin significantly reduce the immobility time and increased swimming time of FST, which are compared with the vehicle 
(P < 0.05). The extract and rutin also increase the serotonin, norepinephrine, and dopamine concentration of these brain regions (P < 
0.05). In long-term tests, the daylily flowers extract markedly increased serotonin concentration and reduced serotonin turnover rate 
in these brain regions but not frontal cortex. In conclusion, present data illustrated that DFEtoH does have antidepressant-like effects 
possibly via the regulation of serotonergic system. Moreover, rutin might be playing a very important role in the antidepressant-like 
effects of DFEtoH.
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of the 10 leading death causes for 13 years since 1997 in Taiwan. 
Research showed that among these suicidal victims, as high as 
97–100% are mentally disordered, and depression accounted 
for 87.1%.[4] Thus, in order to improve social encumbrances and 
reduce suicidal rate, antidepressant and pathological researches 
should be actively pushed forward. 
Unfortunately, the exact pathology of this severe psychiatric 
disorder is not investigated clearly. So far, many pathological hy-
potheses were established upon physiopsychological researches, 
which includes neuroplastiticy reduction induced by hypotha-
lamic–pituitary–adrenal (HPA) axis over activation and chronic 
inflammation.[5-7] Clinical investigations also showed that the 
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cerebral or plasma neurotransmitters were reduced in patients 
with depression.[8-10] Many studies indicate that these pathological 
hypothesis will lead to neuroplasticity reduction, which may be 
the major cause of depression.[7,11]
Antidepressant is the major therapy for MDD patients. Clinical 
observation shows that the depressive symptoms were developed 
by these drugs. The pharmacology of these medicines is inhibi-
tion of neurotransmitter reuptake or blocking metabolic enzymes 
in order to increase neurotransmitter concentration in synapse. 
Moreover, in vitro studies showed that these antidepressants may 
also enhance neuroplasticity.[12] Although antidepressant may be 
the most efficient therapy, these drugs will lead to many trouble-
some side-effects such as nausea, tremor, vomiting, diarrhea, and 
psychomotor activation.[13-15] Alternatively, several in vitro studies 
show many natural products having neural protective effect. In 
vivo investigation also indicates that some functional foods and 
Chinese medicines can improve depression-like behaviors. Thus, 
these functional foods could be valuable for the development of 
antidepressants.
Daylily flower (金針花 Jīn Zhēn Huā ; the flower of Hemero-
callis fulva) is traditionally used for soothing in Chinese dietary 
therapy. The flowers of daylily are rich in variety of antioxidants 
such as carotenoids, flavonoids, anthocyanin, and so on.[16,17] 
Recent studies indicated that daylily flowers greatly improved 
sleeping[18] and memory,[19] along with potent antioxidant ability. 
The alcohol extracts of daylily flowers exhibited better biologi-
cal activities than the aqueous extract.[17,20,21] Research analysis 
of methanol extract of daylily flowers showed that rutin is a key 
component, as high as 19%, which exhibited the best antioxidant 
activity among those components isolated by this extraction 
method.[16] Using tail suspension test as a behavioral model of 
depression-like behavior, studies revealed that mice treated with 
rutin showed a significant reduction of immobility time, suggesting 
a potential antidepressant effect of rutin.[22] The above-mentioned 
studies suggest rutin as a candidate antidepressant chemical, and 
could be the major active component in extract of daylily flowers. 
The most widely used behavioral model for evaluating antide-
pressant effect is forced swimming test (FST), which was estab-
lished by Porsolt in 1979.[23] As a homologous model, the extent 
of depression is determined through observing and measuring rats’ 
behavior in an inescapable transparent water barrel in a defined pe-
riod of time. In this procedure, the accumulated time during which 
the rats remained motionless and no struggling attempt to swim, 
it defined as the immobility time and it represented behavioral 
despair, which imitated in human depression. Longer immobility 
time indicated more serious depression or depression-like behavior. 
Recent neuronal studies indicate that FST increases corticoste-
rone excitation and further lead to new born neuron cell (BrdU+ 
cell) reduction and dysregulation of neurotransmissions.[24-26] 
Previous studies showed that immobility behavior induced by 
the FST can be largely improved by various antidepressants and 
electro-convulsive therapy (ECT).[27-31] Therefore, FST is a suitable 
model to induce depression-like behavior for testing the effect or 
mechanism of antidepressants. 
The aims of this study are (1) to perform content analysis of 
rutin in DFEtoH; (2) to analyze monoamine neurotransmitters and 
their metabolites in the brain; (3) to investigate the antidepressant 
effect of DFEtoH in short-term and long-term treatment using FST; 
and (4) to further understand whether rutin is the major active 
component in extract of daylily flowers.
MATERIALS AND METHODS
Preparation of ethanol extract from dried daylily flowers
The dried daylily flowers we used were purchased from 
Taimali, the main production site of daylily in Taiwan, which 
was processed by the low-sulfur manufacturing methods, and 
was genetically identified as Hemerocallis fulva. In small amount 
preparation method for short-term test, 1 kg powdered daylily 
flowers was added to 20 L 95% ethanol and stirred for 24 hours, 
filtered and then condensed at low pressure following by air dry 
at 37°C for fully removing ethanol, and stored at -20°C. The final 
extraction efficiency is 16.2%. For large-scale preparation used 
for long-term test, 10 kg dried daylily flowers powder was mixed 
with 100 L 95% ethanol and undergoing sonication for 3 hours to 
yield extract, filtered and then condensed at low pressure following 
by air dry at 37°C for fully removing ethanol, and stored at -20°C 
until use. The final extraction efficiency is 10%.
High performance liquid chromatography (HPLC) 
condition for analyzing rutin content of ethanol extract of 
daylily flowers extracted by large-scale preparation method 
The DFEtoH was dissolved in methanol, filtered through a 0.45 
μm membrane, then run through HPLC for analysis. Parameters: 
RP-18 column; water phase contained 5% methanol, 0.2% acetic 
acid and water; organic phase was 100% methanol. Flow rate at 
20 μl/min; detection wavelength at 254 nm; Peak ABC as the data 
analysis software. Rutin standard was purchased from Sigma. After 
calculation, the result showed that each gram of daylily ethanol 
extract contained 7.5 mg of rutin. 
Experimental animals and treatment
Animals were purchased from the Lestco Biotechnology 
company (Yilan, Taiwan) and maintained in animal room whose 
environment was controlled at12 hour/12 hour light/dark cycle and 
temperature at 23±2°C, unlimited water and food pellet (PMI Feed, 
St. Louis, MO, USA), weighed daily for calculating food intake. 
Short-term phase study used 6-week-old male SD rats, randomly 
divided into six groups: normal control (NC), negative control (C), 
fluoxetine (F), low dosage (D), medium dosage (MD), and high 
dosage (HD) of DFEtoH, after prefeeding for 1 week, at 7 weeks 
old, experiment was performed. All samples were dissolved in 
0.5% carboxylmethyl cellulose (CMC) and fed to rats once daily 
for 7 successive days by oral gavage with 0.5% CMC, 18 mg/kg 
fluoxetine, DFEtoH for 3, 15, and 30 g/kg bw raw compound after 
appropriate calculation according to extraction efficiency. Besides 
the NC group, all the other five groups underwent FST after 7 days 
of oral gavage. For long-term experiment, 5-week-old male SD 
rats were randomly divided into six groups: negative control (C), 
fluoxetine (F), low dosage DFEtoH (D), medium dosage (MD), 
high dosage (HD) and rutin (R). After prefeeding for 2 weeks, 
experiment was performed when animals were 7 weeks old. The 
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rats were treated with 0.5% CMC, 18 mg/kg fluoxetine, DFEtoH 
for 3, 15, and 30 g/kg bw raw compound after appropriate calcu-
lation according to extraction efficiency and rutin, equivalent to 
the high dosage group by oral gavage once daily for 28 days, and 
followed by FST. All animals were sacrificed immediately after 
FST and removed brain for analyzing the content of neurotrans-
mitters. Fluoxetine (Prozac®) was purchased from Lily (Taiwan).
Forced swimming test 
Our FST was modified from the method established by Porsolt 
et al. in 1977.[27] A transparent glass barrel with diameter of 21 
cm was filled with water until 30 cm high, so that the rat cannot 
reach the bottom. After oral gavage at the last day, day 7 or day 28, 
all rats except the NC group were placed in the barrel for 15-min 
pretest, followed by towel drying and drying apparatus warmed, 
then placed back into the cage. After 24 hours, a similar 5-min test 
was performed, and tape recorded. Rat behaviors can be distin-
guished as struggling, swimming, and immobility. The struggling 
was defined as animal vigorously swam vertical. The swimming 
was defined as swimming slowly and circling around the barrel. 
Immobility time was the index of rat behavioral despair, and its 
duration will be used for determining the extent of depression. 
Analysis of brain monoamine neurotransmitters by HPLC
Extraction of monoamines from brain tissues
After FST, all animals were anesthetized by CO
2
 and sacrificed 
by decapitation. The brain was removed immediately, divided into 
frontal cortex, striatum, hippocampus, and amygdala on ice accord-
ing to Glowinsk’s method,[32] and stored in -80°C. The method of 
monoamine extraction from brain tissue was modified from Cheng.
[33] Extraction solvent was modified into 10-7M ascorbic acid, 1.5 
mg/100 ml pargyline, and 50 pg/μl isoproterenol in 0.1N HCl. All 
brain tissues were homogenized with 5 ml extraction solvent, then 
centrifuged at 10000 × g for 20 min at 4°C. The supernatant was 
stored in -80°C for further analysis. 
Analyzing monoamine by HPLC
Supernatant of brain tissues was filtered through a 0.45 μm 
membrane, analyzed for serotonin (5-HT), dopamine (DA), 
norepinephrine (NE), 5-hydroxyindoleacetic acid (5-HIAA), 
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA) contents using HPLC coupled by electrochemical detec-
tor (ECD). All standards were purchased from Sigma. Column: 
Alltech Apollo C18, 5 μ, 4.6 × 250 mm; guard column: Meta 
Guard C18-A, Polaris, 5 μ, 7.5 × 4.6 mm; data analysis software: 
Peak ABC; electroprobe: C-KCl reference electrode (BAS, West 
Lafayette, IN, USA); pump: Pump PM-92E (BAS, West Lafayette, 
IN, USA); electrochemical detector: Amperometric Detector LC-
4C (BAS, West Lafayette, IN, USA).
Parameters for analysis of NE, DA, DPOAC: electrochemical 
detector: range 10.0 nA, filter 0.1 Hz, AppE cell 0.75 V; mobile 
phase: 20.5 g NaH
2
PO
4
, 185 mg EDTA, 130 mg SOS (1-octane-
sulfonic acid, sodium salt) and 107 ml methanol per liter; flow 
rate: 500 μl/min. Parameters for analysis of 5-HT, 5-HIAA, HVA: 
electrochemical detector: range 5.0 nA, filter 0.1 Hz, AppE cell 
0.75 V; mobile phase: 20.5 g NaH
2
PO
4
, 185 mg EDTA, 130 mg 
SOS and 200 ml methanol per liter; flow rate: 500 μl/min.
Statistical analysis
All data were analyzed by one-way analysis of variance 
(ANOVA) and Duncan’s new multiple range test for comparing 
differences between groups by using SAS statistical software, 
version 9.0. 
RESULTS
Rutin content of daylily flowers ethanol extract
Rutin content is analyzed by HPLC and used standard to 
quantify. The peak of rutin in each sample will appear for about 
12 min after injection [Figure 1]. Rutin concentration of small-
scale and large-scale extraction are 7.85 ± 0.23 and 7.45 ± 0.17 
(mg/g ethanol extract). 
Antidepressant effect
In this study, FST is used to investigate the antidepressant 
effect of daylily flowers ethanol extract. Rat behaviors can be 
distinguished as struggling, swimming, and immobility. The dura-
tion of immobility behavior is related to the despair thinking and 
the depression-like level. The results revealed that all rats treated 
with the DFEtoH had a significant reduction of immobility time 
in both short-term and long-term experiments. Groups of medium 
dosage, high dosage, and rutin had similar effect as fluoxetine in 
long-term treatment. Further investigation of swimming behavior, 
all treatment groups, except for low dosage in long-term experi-
Figure 1. The chromatogram of rutin standard and DFEtoH. (A) Rutin 
(B) large-scale extraction (C) small-scale extraction
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ment, had increased swimming time without affecting struggling 
time [Figure 2].
Neurotransmitter determination and metabolic rate
Neurotransmitters reduction and metabolic rate increasing are 
discovered in MDD patients and depress-like induced animals. In 
this study, monoamines, the major mood-related neurotransmitters 
are detected by HPLC. 
In the acute experiments, serotonin content of amygdala of each 
daylily flowers treatments (D, MD, and HD) were significantly 
increased, which were compared to FST-induced rats and had no 
difference with normal control. However, there was no difference 
in frontal cortex and hippocampus [Table 1A]. The metabolic rate 
of serotonin of depression-like rats was higher than normal control. 
After daylily flowers extract or antidepressant treating, the meta-
bolic rate was significant reduced [Figure 3A]. Norepinephrine 
concentration of high dosage group in amygdala was significantly 
higher than the negative control. In this dosage, norepinephrine 
in amygdala was not different between normal rats [Table 1B]. 
Figure 2. The rat behaviors under forced swimming test. (A) Short-term experiment (B) long-term experiment. C: negative control; F: fluoxetine; D: 
low dosage of ethanol extract of daylily flowers; MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH; R: rutin. abcd data not sharing the same 
letter are significantly different from one another in each group (P < 0.05) by ANOVA and Duncan’s multiple range test
Figure 3: The metabolic rate of monoamines in acute experiment. (A) Serotonin in amygdala (B) dopamine in striatum. NC: normal control, C: negative 
control; F: fluoxetine; D: low dosage of DFEtoH; MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH. abc data not sharing the same letter 
are significantly different from one another in each group (P < 0.05) by ANOVA and Duncan’s multiple range test
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Dopamine concentration of all dosage was significant difference 
in striatum. Furthermore, the calculation of the ratio of dopamine 
and its metabolite in the striatum, the metabolic rate of dopamine 
was reduced [Figure 3B]. But in other brain regions, there is no 
difference between daylily flowers treatments and normal control 
[Table 1C]. These results can indicate that the DFEtoH can influ-
ence some neurotransmitters in brain in short time. 
There was difference between acute and chronic experiments 
for serotonin status. Unlike acute test, not only in amygdala but 
also in frontal cortex and hippocampus, MD and HD can signifi-
cantly elevate serotonin level. Only high dosage treatment can 
affect serotonin concentration in striatum [Table 2A]. The results 
of metabolic rate are corresponding with neurotransmitter content. 
In amygdala and hippocampus, all dosage of extract can signifi-
cantly reduce the metabolic rate of serotonin [Figure 4A and B]. 
In striatum, only high dosage can reduce metabolic rate [Figure 
4C]. However, there is no effect in frontal cortex [Figure 4D]. All 
treatments can influence norepinephrine content in amygdala, but 
only HD group had significant difference in hippocampus. How-
ever, it was not similar to acute study, the ethonal extract cannot 
influence norepinephrine in frontal cortex and striatum [Table 2B]. 
For dopamine, there was no change in amygdala, hippocampus and 
frontal cortex but not in striatum [Table 2C]. Dopamine metabolic 
rate was also found to be reduced in each dosage groups [Figure 5]. 
DISCUSSION
For the antioxidant capacity, previous study shows that the 
Table 1. The concentration of monoamines in four brain regions in acute test. (A) Serotonin (B) Norepinephrine (C) Dopamine
(A) Serotonin
Groups ng/g Brain tissue
Amygdala Frontal cortex Hippocampus Striatum
NC 204 ± 52ab 115 ± 18 103 ± 35 262 ± 13ab
C 31 ± 14c 108 ± 25 73 ± 32 233 ± 42b
F 168 ± 30b 108 ± 7 210 ± 287 299 ± 56a
D 141 ± 28b 128 ± 27 107 ± 23 290 ± 24a
MD 208 ± 98ab 135 ± 22 80 ± 13 268 ± 20ab
HD 256 ± 12a 123 ± 29 137 ± 24 305 ± 36a
Data are expressed as means ± SD (n=4). All samples were administered once daily for 7 days by oral gavage. 5-HT: serotonin, 5-hydroxytryptophan. NC: 
normal control; C: negative control; F: fluoxetine; D: low dosage of DFEtoH; MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH. abcSignificantly 
different from the control group of each brain region (P < 0.05) by ANOVA and Duncan’s multiple range test.
(B) Norepinephrine
Groups ng/g Brain tissue 
Amygdala Frontal cortex Hippocampus Striatum 
NC 245 ± 125a 206 ± 30a 212 ± 99 189 ± 51 
C 73 ± 62c 96 ± 11c 107 ± 12 180 ± 27 
F 153 ± 46abc 98 ± 12c 140 ± 90 198 ± 35 
D 97 ± 15bc 125 ± 15bc  147 ± 82  185 ± 14  
MD 160 ± 52abc  201 ± 58a  135 ± 127 208 ± 37  
HD 206 ± 64ab  166 ± 40ab  192 ± 83 205 ± 21  
Data are expressed as means ± SD (n=4). All samples were administered once daily for 7 days by oral gavage. NE: norepinephrine. NC: normal control; C: 
negative control; F: fluoxetine; D: low dosage of DFEtoH; MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH. abc Significantly different from the 
control group of each brain region (P < 0.05) by ANOVA and Duncan’s multiple range test.
(C) Dopamine
Groups ng/g Brain tissue
Amygdala Frontal cortex Hippocampus Striatum
NC 382 ± 127a  281 ± 69  117 ± 37a  2774 ± 171a  
C 370 ± 118a  296 ± 68 79 ± 16ab  1768 ± 84d  
F 218 ± 35b  324 ± 114  79 ± 21ab  2120 ± 122c  
D 268 ± 26ab  305 ± 39  84 ± 16ab  2093 ± 87c  
MD 378 ± 63a  322 ± 52  75 ± 26b  2267 ± 187c  
HD 316 ± 102ab 252 ± 38  94 ± 25ab  2531 ± 182b  
Data are expressed as means ± SD (n=4). All samples were administered once daily for 7 days by oral gavage. DA: dopamine. NC: normal control; C: 
negative control; F: fluoxetine; D: low dosage of DFEtoH; MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH. abcd Significantly different from 
the control group of each brain region (P < 0.05) by ANOVA and Duncan’s multiple range test.
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ethanol extract is better than the water extract, which is according 
to the high phenolic compound containing rutin, catechin, and 
gallic acid.[17] Our previous experiment also indicates that these 
phenols are highly contained in ethanol extract but not in water 
extract (data not shown). Rutin is a well known phenolic com-
pound, which exist in many herbals. The famous antidepressive 
functional food, St. John’s wort claims that the rutin is abundant 
inside. The ethanol extract of Schinus molle L., a rutin-rich herbal, 
can reduce the immobility time of mice in the tail suspension 
test.[22] In this study, the extraction rate of small and large scale is 
16.8% and 10%, rutin is 7.85% and 7.45% content in these extracts, 
respectively. Thus, we aim at investigating whether the DFEtoH, a 
rutin-rich plant, has antidepressive effect or not. To the best of our 
knowledge, this study is the first to investigate the antidepressive 
effect of DFEtoH. Thus, this study is a pioneer research of daylily 
flowers and its antidepressant function.
FST is a common model for antidepressant screening. In this 
model, rats are forced to swim for 15 min at first day and for 5 min 
24 hours later. It mimics the high stress level in order to induce 
the depression-like behavior in rats, which is regarded as hopeless 
thinking of human being. Physiological studies show FST can 
cause over secretion of corticosterone.[25,34] This situation is similar 
to humans who are under stress and HPA axis dysregulation occurs. 
Normal concentration of corticosterone stimulates neuronal devel-
opment.[35] However, in vitro studies show that over secretion of 
corticorsterone will lead calcium influx deucedly and finally cause 
neuronal cell death.[36-38] The reduction of neuroplasticity may be 
the convergent point of each depression hypothesis. The plastic-
Table 2. The concentration of monoamines in four brain regions in chronic test. (A) Serotonin (B) Norepinephrine (C) Dopamin
(A) Serotonin
Groups ng/g Brain tissue
Amygdala Frontal cortex Hippocampus Striatum
C 181 ± 32c 264 ± 33c 174 ± 18c 941 ± 40bc 
F 528 ± 232a 234 ± 40c 222 ± 30b 906 ± 45c 
D 268 ± 83bc 307 ± 12b 226 ± 28b 923 ± 38c 
MD 303 ± 45b 327 ± 28ab 246 ± 29ab 969 ± 62ab 
HD 357 ± 70b 354 ± 18a 262 ± 35a 985 ± 30 a 
R 316 ± 69b 299 ± 37d 246 ± 19ab 931 ± 17bc 
Data are expressed as means ± SD (n=8). All samples were administered once daily for 28 days by oral gavage. 5-HT: serotonin, 5-hydroxytryptophan. C: 
negative control; F: fluoxetine; D: low dosage of DFEtoH; MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH; R:rutin. abcd Significantly different 
from the control group of each brain region (P < 0.05) by ANOVA and Duncan’s multiple range test.
(B) Norepinephrine
Groups ng/g Brain tissue
Amygdala Frontal cortex Hippocampus Striatum
C 130 ± 24c 231 ± 22b 220 ± 17c 277 ± 41b
F 186 ± 50b 231 ± 26b 286 ± 43bc  318 ± 40ab 
D 189 ± 29b 238 ± 19b 249 ± 36bc 302 ± 29ab 
MD 215 ± 24ab 250 ± 15b 268 ± 35bc 269 ± 62b 
HD 242 ± 14a 253 ± 32b 299 ± 44b 294 ± 36ab 
R 239 ± 28a 298 ± 50a 350 ± 45a 342 ± 66a 
Data are expressed as means ± SD (n=8). All samples were administered once daily for 28 days by oral gavage. NE: norepinephrine. C: negative control; F: 
fluoxetine; D: low dosage of DFEtoH; MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH; R:rutin. abc Significantly different from the control 
group of each brain region (P < 0.05) by ANOVA and Duncan’s multiple range test.
(C) Dopamine
Groups ng/g Brain tissue
Amygdala Frontal cortex Hippocampus Striatum
C 58 ± 18 298 ± 65a 13 ± 3 3710 ± 205c 
F 60 ± 23 223 ± 55b 16 ± 5 3394 ± 298d 
D 65 ± 22 283 ± 59ab 18 ± 4 3843 ± 427c 
MD 59 ± 21 322 ± 98a 15 ± 4 4700 ± 135ab 
HD 68 ± 20 288 ± 55ab 14 ± 4 4462 ± 224b 
R 65 ± 30 218 ± 62b 17 ± 10 4790 ± 297a 
Data are expressed as means ± SD (n=8). All samples were administered once daily for 28 days by oral gavage. DA: dopamine. C: negative control; F: 
fluoxetine; D: low dosage of DFEtoH; MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH; R:rutin. abcd Significantly different from the control 
group of each brain region (P < 0.05) by ANOVA and Duncan’s multiple range test.
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ity of neuron includes the increase of neuron numbers, structure 
remodeling, and neurogenesis.[39] However, studies show stress-
induced neuroplastiticy in both human and animal models.[7,40,41] 
Accordingly, FST is a feasible stress-induced model for mimicking 
human-like depressive behavior and neuronal alteration. In this 
study, either in acute or in chronic experiments, the immobility 
time is significantly reduced by DFEtoH treating. In acute test, 
three dosages of extract have the same consequent as fluoxetine 
[Figure 2A]. Moreover, medium and high dosages have similar 
results as fluoxetine [Figure 2B]. This discovery represents that the 
DFEtoH have potential antidepressant activity. In other behaviors, 
the extract of daylily flowers only influences swimming duration 
but not struggling. Either in acute or in chronic tests, the swimming 
duration of treatment groups is significantly enhanced compared 
with negative control, and it also has similar effect as the positive 
control, the selective serotonin reuptake inhibitor (SSRI), fluox-
etine [Figure 2]. Swimming is the one of three major behaviors 
of rats during FST. This behavior is controlled by serotonergic 
system. Many studies show that swimming behavior duration 
will be elevated by SSRI treated.[30,31,42] The last major behavior 
is struggling, which is controlled by noradrenergic system.[29,30] 
However, struggling behavior did not change by any treatment in 
this study [Figure 2]. This behavioral investigation indicates that 
the antidepressant effect of daylily flowers extract may result in 
affecting serotonergic neuron or serotonin concentration.
Clinical studies show that depression patients have lower 
monoamines content in cerebrum.[8,43,44] It may be caused due to 
overactivation of monoamine receptors or hypermetabolic rate.
[45-47] Therefore, a common strategy for the treatment of MDD 
patients is to use antidepressants that alter monoamine oxidase 
(MAO) activity and monoamine reuptake. In this study, serotonin 
has got the most evidence, especially in amygdala. In this brain 
region, all dosages of daylily extract can increase serotonin con-
tent and have no difference between normal rats. In the chronic 
test, it is more effective on increasing serotonin concentration in 
these brain regions. The relationship between neurotransmitters 
and FST behaviors are mentioned as above. Thus, such alteration 
may reflect the observed behavioral change in rats in the FST. The 
extract of daylily flowers appears to have the least or no effect on 
the dopaminergic system, except the dopamine level in the stria-
tum. Further, we detect the metabolites of these neurotransmitters 
in order to know the metabolic rate. Although the contributions of 
neurotransmitters and its metabolites in patients with depression 
are unclear, we can calculate the ration of monoamines and its 
metabolite as an index to evaluate the effect of antidepressants. 
For example, research indicates that the serotonin metabolic rate 
in rat hippocampus was blocked by 10 days treatment of fluoxetine 
(20 mg/kg/day) or other serotonin-type antidepressant treating.[48,49] 
Our study shows that serotogenic system is the most effective 
target of daylily flowers. In acute test, 82.5–86.6% serotonin 
metabolic rate in amygdala is blocked, which is comparable 
between extract and negative control [Figure 3A]. However, 
in chronic test, the serotonin metabolic rate is also reduced in 
amygdala, hippocampus, and striatum for 40–60%, 30–47.9%, 
and 18.3–40.7%, respectively. Based on these results, we suggest 
the antidepressant mechanism of daylily ethnol extract is through 
reducing monoamine oxidase activity or metabolism. Monoamine 
oxidase is the metabolic enzymes of monoamines in synapse and 
cleft. These enzymes could be classified into MAO-A and MAO-
B. In vivo study shows that MAO-A mutant mice could represent 
similar behavior as MAO-A deficient human and the monoamines 
concentration are significantly higher than wide type. However, 
this deamination reaction results produce hydrogen peroxide in 
brain.[50] Oxidative stress can lead to neuron cell apoptosis and 
neuroplasticity reduction.[6,51] In vivo and clinical studies also 
indicate that monoamine oxidase hyperactivity was observed in 
some MDD patients or depression-like animals.[52,53] This situa-
tion may not only cause neurotransmitters reduction but also raise 
oxidative stress and lead to neurotoxicity. Some researches show 
that some phytochemicals have inhibition of MAO activity and 
neuroprotective function. Some of these phytochemicals are rich 
Figure 4. The metabolic rate of serotonin in chronic experiment in each 
brain regions. (A) Amygdala (B) hippocampus (C) striatum (D) frontal 
cortex. C: negative control; F: fluoxetine; D: low dosage of DFEtoH; MD: 
medium dosage of DFEtoH; HD: high dosage of DFEtoH; R: rutin. abcd 
data not sharing the same letter are significantly different from one another 
in each group (P < 0.05) by ANOVA and Duncan’s multiple range test
Figure 5. The metabolic rate of dopamine in chronic experiment in 
striatum. C: Negative control; F: fluoxetine; D: low dosage of DFEtoH; 
MD: medium dosage of DFEtoH; HD: high dosage of DFEtoH; R: rutin. 
abcde data not sharing the same letter are significantly different from one 
another in each group (P < 0.05) by ANOVA and Duncan’s multiple 
range test.
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in ethanol of daylily flowers extract such as rutin, isoquercitrin, 
and quercetin.[54] The MAO-A inhibition function of quercetin has 
been discovered.[55] In this study, we investigated that the ethanol 
extract can highly affect the serotonergic system. Therefore, we 
surmise that the antidepressant effect may be contributed by MAO 
inhibitor function. However, the antidepressant effect of rutin is 
lower than the high dosage extract group in chronic test [Figure 
2B]. It indicates that daylily flower extract may have other nutri-
ents, which can affect the depressive-like behavior. 
In conclusion, the DFEtoH can provide rutin and other phenolic 
compounds, which can reduce the immobility behavior. This effect 
may through blocking monoamine oxdase and elevate the synaptic 
neurotransmitter concentration. However, the clearly mechanism 
should be investigated in the future. 
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